In the aftermath of one of Silicon Valley’s most infamous frauds, the biotech sector finds itself confronting an uncomfortable echo. Elizabeth Holmes—still serving time for the Theranos scandal—is once again adjacent to the world of health innovation. This time, it's through her partner, Billy Evans, who now leads a startup called Haemanthus. On paper, Hemanthus blends legitimate technologies: Raman spectroscopy and deep learning models aimed at fluid-based diagnostics. The i

With U.S. tariffs on Chinese goods now reaching up to 245 percent, the world’s largest trading relationship has crossed a structural threshold. While Beijing contests the measures, early signals suggest that China’s ability—or willingness—to absorb the shock is limited. For growth‑stage companies and investors, the next decade will be defined by how quickly supply chains diversify, how smoothly capital reallocates, and which jurisdictions capture the incremental value that on